Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Margetuximab - MacroGenics

X
Drug Profile

Margetuximab - MacroGenics

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MARGENZA; Margetuximab-cmkb; MGAH-22

Latest Information Update: 03 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Raven biotechnologies
  • Developer GC Biopharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • Phase II/III Gastric cancer; Oesophageal cancer
  • Phase I Haematological malignancies; Solid tumours
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 03 Apr 2023 Margetuximab is still in phase I trials for Solid tumors (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Bulgaria, Australia, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
  • 03 Apr 2023 Margetuximab is still in phase I trials for Haematological-malignancies(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Bulgaria, Australia, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
  • 27 Mar 2023 MacroGenics completes phase I trial for Haematological malignancies and Solid tumors (Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (NCT03219268)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top